Virica Biotech
Latest round
- Series A
Last raised
- Oct 2021
Total raised
- Undisclosed
Investors
- 1
About Virica Biotech
Virica Biotech Inc.Virica Biotech Inc. develops solutions to optimize viral vector production for therapies and vaccines. Founded in 2018, the company is headquartered in Ottawa, Canada. The founders include Ella Korets-Smith and Jean-Simon Diallo, with Jean-Simon Diallo serving as the CEO.Virica Biotech specializes in enhancing the manufacturing processes of cell and gene therapies as well as vaccines through its proprietary library of small molecule cell enhancers known as Viral Sensitizers (VSE™). These enhancers function by temporarily reducing innate cellular defenses during viral vector production, thereby allowing for improved infection, transduction, and replication of viruses. The enhancements achieved through VSEs have been reported to yield up to a sevenfold increase in productivity, while also improving critical quality attributes (CQAs) of the final products. Virica's offerings serve a diverse clientele, including cell and gene therapy manufacturers and vaccine producers, across various geographical markets including North America, Europe, and Asia.Virica Biotech's revenue is generated primarily through partnerships with biotechnology and pharmaceutical companies that utilize its VSE technology. The transaction structure typically involves B2B relationships where clients engage in collaborative agreements for the use of VSEs in their production processes. These arrangements may include licensing agreements, service contracts, or project-based collaborations tailored to specific applications within cell and gene therapy and vaccine production. The company offers its VSEs as part of a comprehensive service portfolio designed to optimize manufacturing productivity and reduce costs, further facilitating client research and development activities.In October 2021, Virica Biotech Inc. The company will use the investment to further support the launching of its new lab facility which is a part of the Ottawa Health Innovation Hub as part of its expansion. Virica plans to enhance its product offerings and expand into new markets, targeting growth in regions such as Asia and Europe by mid-2023.
Who invested in Virica Biotech
1 investor across 1 round
See all investors in Virica Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 4, 2021
Amount
Undisclosed
Investors
Questions about Virica Biotech
Who invested in Virica Biotech?
Virica Biotech has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Virica Biotech raised?
Virica Biotech has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Virica Biotech last raise money?
Virica Biotech's most recent round on record is a Series A, in Oct 2021.
What does Virica Biotech do?
Virica Biotech is a biotechnology company.
Where is Virica Biotech headquartered?
Virica Biotech is headquartered in Ottawa, Canada.
Which VCs invest in companies like Virica Biotech?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Virica Biotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Virica Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.